TY  - GEN
AU  - Hughes,Derralynn A
AU  - Nicholls,Kathleen
AU  - Shankar,Suma P
AU  - Sunder-Plassmann,Gere
AU  - Koeller,David
AU  - Nedd,Khan
AU  - Vockley,Gerard
AU  - Hamazaki,Takashi
AU  - Lachmann,Robin
AU  - Ohashi,Toya
AU  - Olivotto,Iacopo
AU  - Sakai,Norio
AU  - Deegan,Patrick
AU  - Dimmock,David
AU  - Eyskens,François
AU  - Germain,Dominique P
AU  - Goker-Alpan,Ozlem
AU  - Hachulla,Eric
AU  - Jovanovic,Ana
AU  - Lourenco,Charles M
AU  - Narita,Ichiei
AU  - Thomas,Mark
AU  - Wilcox,William R
AU  - Bichet,Daniel G
AU  - Schiffmann,Raphael
AU  - Ludington,Elizabeth
AU  - Viereck,Christopher
AU  - Kirk,John
AU  - Yu,Julie
AU  - Johnson,Franklin
AU  - Boudes,Pol
AU  - Benjamin,Elfrida R
AU  - Lockhart,David J
AU  - Barlow,Carrolee
AU  - Skuban,Nina
AU  - Castelli,Jeffrey P
AU  - Barth,Jay
AU  - Feldt-Rasmussen,Ulla
TI  - Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
SN  - 1468-6244
PY  - 2017///1103
KW  - 1-Deoxynojirimycin
KW  - administration & dosage
KW  - Administration, Oral
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Enzyme Replacement Therapy
KW  - adverse effects
KW  - Fabry Disease
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Lysosomes
KW  - genetics
KW  - Male
KW  - Middle Aged
KW  - Molecular Chaperones
KW  - Treatment Outcome
KW  - alpha-Galactosidase
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1136/jmedgenet-2016-104178
ER  -